GlassScriptPhysician profile
James N Esserman
NPI 1699719997
$2,638.84
in general payments reported to CMS, 2019-2025
25 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $219 · 2021: $242 · 2022: $388 · 2023: $611 · 2024: $264 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.23 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $311.02 | 2019-2025 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $290.18 | 2019-2025 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Abbvie INC. | $260.88 | 2019-2022 | |
| Radius Health, INC. | $250.04 | 2019-2022 | |
| Pfizer INC. | $205.48 | 2019-2024 | |
| Astellas Pharma US INC | $182.32 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $180.08 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.21 | 2019-2023 | |
| Amag Pharmaceuticals, INC. | $103.20 | 2019 | |
| Vertical Pharmaceuticals, LLC | $96.47 | 2019 | |
| Sumitomo Pharma America, INC. | $89.62 | 2023-2025 | Myfembree |
| Exact Sciences Corporation | $82.34 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Organon LLC | $78.99 | 2022-2024 | |
| Therapeuticsmd, INC. | $75.25 | 2019-2022 | |
| Coopersurgical, INC. | $66.43 | 2022-2024 | Paragard T 380a, Paragard T 380a |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $52.07 | 2019 | |
| Myovant Sciences INC. | $41.58 | 2022 | |
| Millicent US INC | $33.14 | 2020-2024 | Intrarosa, Femring |
| Merck Sharp & Dohme LLC | $31.13 | 2019-2022 | |
| Sage Therapeutics, LLC | $21.76 | 2023 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Avion Pharmaceuticals | $15.99 | 2023 | Balcoltra |
| Allergan, INC. | $14.80 | 2019 | |
| Lupin INC. | $14.74 | 2019 | |
| Meditrina | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Esserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.